Delhi HC Plea Seeks Urgent BMT Funds for 3-Year-Old Girl

A recent Delhi High Court petition highlights the struggle of families accessing rare disease funds. A three-year-old girl with LRBA deficiency urgently needs a life-saving bone marrow transplant. Although the National Policy for Rare Diseases 2021 provides financial aid, bureaucratic delays often stall treatment. Therefore, legal intervention becomes the last resort for many desperate families.

Understanding LRBA Deficiency and Its Treatment

LRBA deficiency represents a rare, severe genetic disorder that impairs immune regulation. Consequently, patients suffer from recurrent infections and multi-organ autoimmune complications. In this case, doctors determined that a bone marrow transplant offers the only curative option. However, the estimated procedure cost is Rs 40 lakh. Thus, specialists recommended a haploidentical transplant using a half-matched donor, underscoring the complexities managed by those pursuing advanced clinical training in paediatrics.

Challenges in Accessing Rare Disease Funds

The child’s family applied for financial assistance under the revised guidelines. Indeed, the Union Health Ministry enhanced the limit of rare disease funds to Rs 50 lakh in May 2022. However, the government has not yet released the money despite repeated representations. This delay forced the father to approach the High Court. Furthermore, government hospitals like AIIMS Delhi admitted they lack the specialized infrastructure for this complex transplant.

The Constitutional Obligation of the State

The petition argues that delaying this funding violates the Right to Life under Article 21. Additionally, the petition cites landmark Supreme Court judgments to assert that public health remains a primary State responsibility. Thus, the government must fund treatment at appropriate private institutions when public hospitals cannot provide the care. Ultimately, any further delay could cause irreversible damage or organ failure in the young patient, highlighting the critical need for skilled professionals in intensive care medicine to support such fragile cases.

Frequently Asked Questions

Q1: What is LRBA deficiency, and how is it treated?

LRBA deficiency is a rare genetic disorder that disrupts immune system regulation. This condition makes patients highly vulnerable to severe infections and autoimmune issues. Currently, a bone marrow transplant represents the only curative treatment available.

Q2: How much financial aid does India provide for rare diseases?

Under the National Policy for Rare Diseases 2021, the Ministry of Health and Family Welfare offers financial assistance. Specifically, an amendment in May 2022 increased the maximum grant to Rs 50 lakh per patient, a topic often explored in depth within our clinical fellowship programmes in paediatrics.

References

1. Plea moved in Delhi HC seeking immediate release of rare disease funds for3-year-old girl’s life-saving bone marrow transplant – ETHealthworld
2. National Policy for Rare Diseases, 2021 – Ministry of Health and Family Welfare, Government of India
3. Long-term outcome of LRBA deficiency in 76 patients – Immune Deficiency and Dysregulation Activity Study

Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.